SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Arcolab’s subsidiary receives European approval for its Oral Dosage Oncology facility

01 Jul 2011 Evaluate

Onco Therapies, a division of Agila, which is a wholly owned subsidiary of Strides Arcolab, has received European approval for its Oral Dosage Oncology facility (tablet and hard gelatine capsules) in Bangalore. The injectable facility within the Oncology complex has already been approved by all major regulatory agencies. Thus, the facility is now amongst a few European approved Oral Dosage oncology plants worldwide.

Further, the company expects to commercialize 2 products in Europe during Q3 2011. The state of art Oncology complex which was established in 2009 manufactures injectables, oral products (tablets and soft gels) in the oncology domain. It has been built to the most exacting standards, meeting the requirements of the regulatory authorities in the most stringent global markets and is already approved by all the major regulatory authorities following the company to sell off globally.

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the company’s restricting in 2009. It is focused on key domains such as oncologyistics,  penems, pencillins, cephalosphrins, opthalmics, peptides and biosimilars and operates  from 8  world class global  manufacturing facilities, including one of the largest  steriles capacity in India and amongst the  largest lyophilizations  capacities in the world.

Strides Pharma Scien Share Price

1153.90 -1.95 (-0.17%)
11-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1282.15
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2249.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×